Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations

NCT06335355 is registered in ClinicalTrials.gov with Shanghai Shengdi Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06335355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06335355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations
Lead sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
March 31, 2024
Completion date
October 31, 2030
Enrollment
401 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer